---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-206176"
form_type: "8-K"
ticker: null
cik: "0001576263"
company_name: "Mirati Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:56:17.494439+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirati CEO David Meek departs; Charles Baum interim CEO; Q2 net loss $176.9M, KRAZATI rev $13.4M

## Summary
- CEO David Meek resigned Aug 7, 2023; founder Charles Baum named interim CEO; Meek remains consultant through Oct 15.
- Q2 net loss $176.9M ($3.04/sh); KRAZATI revenue $13.4M; cash $779.4M; FY23 net cash burn guidance $560-580M.
- Plans Phase 3 adagrasib + pembro in 1L NSCLC TPS≥50% by year-end; CHMP issued negative opinion on conditional MAA.
- MRTX1719 initial data show favorable safety and early activity in MTAP-deleted cancers; Phase 2 planned H1 2024.

## SEC filing metadata
- accession: 0001193125-23-206176
- form_type: 8-K
- cik: 0001576263
- company_name: Mirati Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/d499867d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-206176
- JSON: https://secwatch.observer/filing/0001193125-23-206176.json
- Plain text: https://secwatch.observer/filing/0001193125-23-206176.txt

## Key facts
- Earnings Releases
  Mirati Therapeutics, Inc. reported financial results for second quarter 2023.
  - Period: second quarter 2023
  - Result: reported results
  source text: On August 8, 2023, Mirati Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm
- Executive change
  David Meek resigned as Chief Executive Officer at Mirati Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On August 7, 2023 (the “Meek Separation Date”), David Meek resigned as a member of the Company’s board of directors and as the Company’s Chief Executive Officer and principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm
- Executive change
  Charles M. Baum was appointed as Interim Chief Executive Officer at Mirati Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: The Company’s board of directors has, effective as of the Meek Separation Date, appointed Charles M. Baum, M.D., Ph.D., in addition to his other titles, as Interim Chief Executive Officer of the Company and as the Company’s principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576263/000119312523206176/0001193125-23-206176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.